Richard Adair, Virology Manager, SGS Vitrology Limited

Richard Adair | Virology Manager | SGS Vitrology Limited » speaking at Advanced Therapies

Karin Agerman, CSO, CombiGene

Karin Agerman | CSO | CombiGene » speaking at Advanced Therapies

Omar Aljitawi, Professor, University of Rochester Medical Center

Omar Aljitawi | Professor | University of Rochester Medical Center » speaking at Advanced Therapies

Amina Al-Mossawi, Qualified Person, UCL/ Hitech Health

Nicola Ambler, Founder, The CGT Circle

Nicola Ambler | Founder | The CGT Circle » speaking at Advanced Therapies

Adrien Auffret Cariou, Team lead – Process Development Projects, SK Pharmteco

Michael Baker, Senior Director Viral Gene Therapy, FUJIFILM Diosynth Biotechnologies

Chris Baldwin, Senior Director of Cell and Gene Therapy Supply Chain, GlaxoSmithKline Plc

Chris Baldwin | Senior Director of Cell and Gene Therapy Supply Chain | GlaxoSmithKline Plc » speaking at Advanced Therapies

Robert Balfour, Investment Director, Alsa Ventures

Robert Balfour | Investment Director | Alsa Ventures » speaking at Advanced Therapies

Tomasz Baran, Executive VP, PBKM/FamiCord Group

Ivana Barbaric, Professor of Stem Cell Biology, The University of Sheffield

Ivana Barbaric | Professor of Stem Cell Biology | The University of Sheffield » speaking at Advanced Therapies

Samantha Barber, Chief Executive Officer, Gene People

Samantha Barber | Chief Executive Officer | Gene People » speaking at Advanced Therapies

Kate Barclay, Skills Strategy Consultant, UK Bioindustry Association

Piotr Barski, Chief Executive Officer, University of Pisa

Piotr Barski | Chief Executive Officer | University of Pisa » speaking at Advanced Therapies

Pranetha Baskaran, Senior Programme Manager, MedCity

Roy Baynes, Senior Vice President Clinical Research, Eikon Therapeutics

Roy Baynes | Senior Vice President Clinical Research | Eikon Therapeutics » speaking at Advanced Therapies

Benedikt Berninger, Professor of Developmental Neurobiology, King's College London

Benedikt Berninger | Professor of Developmental Neurobiology | King's College London » speaking at Advanced Therapies

Niklas Beschorner, Head of Rnd, PROVIREX Genome Editing Therapies GmbH

Anne Black, QA Specialist Pharmacist, NHS Specialist Pharmacy Service

Anne Black | QA Specialist Pharmacist | NHS Specialist Pharmacy Service » speaking at Advanced Therapies

Thomas Bols, Head of Government Affairs and Patient Advocacy, EMEA, PTC Therapeutics

Simon Bornschein, Founder & Chief Executive Officer, coding.bio

Simon Bornschein | Founder & Chief Executive Officer | coding.bio » speaking at Advanced Therapies

John Bridgeman, Director of Cell Therapy Research, Instil Bio

John Bridgeman | Director of Cell Therapy Research | Instil Bio » speaking at Advanced Therapies

Adam Brown, Co-founder and CTO, SynGenSys & Associate Professor of Biopharmaceutical Engineering, University of Sheffield

Adam Brown | Co-founder and CTO, SynGenSys & Associate Professor of Biopharmaceutical Engineering | University of Sheffield » speaking at Advanced Therapies

Oliver Brown, Project Lead, Life Sciences Hub Wales Ltd

Martina Brunati, vector process development manager, AGC Biologics

Emmanuelle Cameau, Strategic Technology Partnership Leader, Cytiva

Emmanuelle Cameau | Strategic Technology Partnership Leader | Cytiva » speaking at Advanced Therapies

Rafael Carazo Salas, Chief Executive Officer, CellVoyant Technologies Ltd

Rafael Carazo Salas | Chief Executive Officer | CellVoyant Technologies Ltd » speaking at Advanced Therapies

Gloria Carmona Sanchez, Scientific Coordinator, Andalusian Network for Advanced Therapies

Paul S Carter, Director, Head Vector Processing, Quell Therapeutics

Paul S Carter | Director, Head Vector Processing | Quell Therapeutics » speaking at Advanced Therapies

Pedro Cejas, Head of New Therapeutic Modalities, Spark Therapeutics

Alex Chalk, Gene Therapy Research Assistant, UCL

Alex Chalk | Gene Therapy Research Assistant | UCL » speaking at Advanced Therapies

Pascale Charbonnel, CBO, SCTbio

Pascale Charbonnel | CBO | SCTbio » speaking at Advanced Therapies

Farhad Chariyev-Prinz, Postdoc, University of Natural Resources and Life Sciences, Vienna

Farhad Chariyev-Prinz | Postdoc | University of Natural Resources and Life Sciences, Vienna » speaking at Advanced Therapies

Fred Chereau, SVP, Strategy and Business Development, Alexion Pharmaceuticals

Fred Chereau | SVP, Strategy and Business Development | Alexion Pharmaceuticals » speaking at Advanced Therapies

Klaus Cichutek, Former President, Paul Ehrlich Institute & Apl. Professor of Biochemistry, Goethe University Frankfurt

Klaus Cichutek | Former President, Paul Ehrlich Institute & Apl. Professor of Biochemistry | Goethe University Frankfurt » speaking at Advanced Therapies

Lindsey Clarke, VP Commercial, The CGT Circle

Angela Columbano, Head Business Development Partnership, Genethon

Angela Columbano | Head Business Development Partnership | Genethon » speaking at Advanced Therapies

Randolph Corteling, CSO, ReNeuron

Randolph Corteling | CSO | ReNeuron » speaking at Advanced Therapies

Elena Costariol, DP MSAT Senior Scientist, Orchard Therapeutics

Elena Costariol | DP MSAT Senior Scientist | Orchard Therapeutics » speaking at Advanced Therapies

Scott Cribbes, Market Development Leader, Revvity

Montserrat Daban, Director of Strategic Foresight and International Relations, Biocat

Eric Michael David, Chief Executive Officer, BridgeBio Gene Therapy

Eric Michael David | Chief Executive Officer | BridgeBio Gene Therapy » speaking at Advanced Therapies

Lindsay Davies, CSO, NextCell Pharma

Lindsay Davies | CSO | NextCell Pharma » speaking at Advanced Therapies

Francesco Dazzi, Professor of Regenerative Medicine, King’s College London Executive & Medical Lead, Cell Therapy, AstraZeneca

Francesco Dazzi | Professor of Regenerative Medicine, King’s College London Executive & Medical Lead, Cell Therapy | AstraZeneca » speaking at Advanced Therapies

Isaak Decoene, Senior Researcher, KU Leuven

Colleen Delaney, Founder, Chief Scientific Officer, Deverra Therapeutics, Inc.

Colleen Delaney | Founder, Chief Scientific Officer | Deverra Therapeutics, Inc. » speaking at Advanced Therapies

Francesca Di Pasquale, Director R&D, QIAGEN GmbH

Michaela Diakatou, Global Product Manager for PSCs and MSCs Clinical Applications, Miltenyi Biotec GmbH

Graciana Diez Roux, Chief Scientific Officer, Tigem

Graciana Diez Roux | Chief Scientific Officer | Tigem » speaking at Advanced Therapies

Graciana Diez-Roux, Chief Scientific Officer, Telethon Institute of Genetics and Medicine

Graciana Diez-Roux | Chief Scientific Officer | Telethon Institute of Genetics and Medicine » speaking at Advanced Therapies

Victor Dillard, VP, Strategy & Operations, Resolution Therapeutics

Victor Dillard | VP, Strategy & Operations | Resolution Therapeutics » speaking at Advanced Therapies

Ben Doak, National Senior Programme of Care Manager (innovative treatments), NHS England

Marcus Droege, Senior Advisor, Market Access & Commercial, EUCOPE - European Confederation of Pharmaceutical Entrepreneurs

Marcus Droege | Senior Advisor, Market Access & Commercial | EUCOPE - European Confederation of Pharmaceutical Entrepreneurs » speaking at Advanced Therapies

Christian Dubiella, Technology Manager – Nucleic Acid Formulation, Wacker Chemie AG

Christian Dubiella | Technology Manager – Nucleic Acid Formulation | Wacker Chemie AG » speaking at Advanced Therapies

Julian Dye, Founder & CEO, Oxartis Ltd

Simon Eaglestone, Director, Program Management, Bloomsbury Genetic Therapies

Thomas M. Ecker, Chief Executive Officer, Ecker+Ecker GmbH

Victoria English, Co-Founder And Editor, Evernow Publications

Victoria English | Co-Founder And Editor | Evernow Publications » speaking at Advanced Therapies

Seth Ettenberg, Chief Executive Officer And President, BlueRock Therapeutics

Lucia Faccio, Partner Sofinnova Telethon Fund, Sofinnova Partners

Lucia Faccio | Partner Sofinnova Telethon Fund | Sofinnova Partners » speaking at Advanced Therapies

Edward Fahey, QCS Director, Scitech Engineering Ltd

Danielle Fairbrass, Group Lead, Cell Biology, coding.bio

Danielle Fairbrass | Group Lead, Cell Biology | coding.bio » speaking at Advanced Therapies

Marcie Finney, Executive Director, Cleveland Cord Blood Center

Gregory Fiore, Chief Executive Officer, Exacis Biotherapeutics

Gregory Fiore | Chief Executive Officer | Exacis Biotherapeutics » speaking at Advanced Therapies

Barry Flutter, Head of Product Manufacturing, GOSH

Barry Flutter | Head of Product Manufacturing | GOSH » speaking at Advanced Therapies

David Foldes, Senior Clinical Research Fellow, Imperial College London

David Foldes | Senior Clinical Research Fellow | Imperial College London » speaking at Advanced Therapies

Katherine Forsey, Chief Research Officer, Charcot Marie Tooth Association

Katherine Forsey | Chief Research Officer | Charcot Marie Tooth Association » speaking at Advanced Therapies

Miguel Forte, President Elect, ISCT; Entrepreneur in Residence, Adbio partners

Miguel Forte | President Elect, ISCT; Entrepreneur in Residence | Adbio partners » speaking at Advanced Therapies

Tim Fugmann, CSO and Co-founder, Alithea Bio

Gonzalo Garcia, Investment Partner, Syncona

Saba Ghassemi, Assistant Professor, University of Pennsylvania

Cédric Ghevaert, Professor in Transfusion Medicine, University of Cambridge

Cédric Ghevaert | Professor in Transfusion Medicine | University of Cambridge » speaking at Advanced Therapies

Daniel Gibson, Director, Cell and Gene Therapy Services, Anthony Nolan

Daniel Gibson | Director, Cell and Gene Therapy Services | Anthony Nolan » speaking at Advanced Therapies

Kurt Gielen, Chief Business Officer, Medace

Kurt Gielen | Chief Business Officer | Medace » speaking at Advanced Therapies

Paul Gissen, Professor of Metabolic Medicine, Head of Gene and Stem Cell Therapy, UCL Great Ormond Street Institute of Child Health

Paul Gissen | Professor of Metabolic Medicine, Head of Gene and Stem Cell Therapy | UCL Great Ormond Street Institute of Child Health » speaking at Advanced Therapies

Janet Glassford, Senior Quality Assessor, Medicines & Healthcare products Regulatory Agency

Janet Glassford | Senior Quality Assessor | Medicines & Healthcare products Regulatory Agency » speaking at Advanced Therapies

Pedro Gonzalez-Alegre, Head of Gene Therapy Research, Spark Therapeutics

Pedro Gonzalez-Alegre | Head of Gene Therapy Research | Spark Therapeutics » speaking at Advanced Therapies

Tom Goodman, Partner, Cooley LLP

Mayur Goyal, Head, Commercial & Pipeline Strategy, Cell & Gene Therapies, Novartis

Mayur Goyal | Head, Commercial & Pipeline Strategy, Cell & Gene Therapies | Novartis » speaking at Advanced Therapies

Roberto Gramignoli, Sr Researcher, Karolinska Institutet

Roberto Gramignoli | Sr Researcher | Karolinska Institutet » speaking at Advanced Therapies

David Greenwald, Vice President Of Business Development, Deerfield Management

David Greenwald | Vice President Of Business Development | Deerfield Management » speaking at Advanced Therapies

Uta Griesenbach, Professor, Molecular Medicine, National Heart And Lung Institute; President, British Society For Gene And Cell Therapy;, Imperiai College London

Uta Griesenbach | Professor, Molecular Medicine, National Heart And Lung Institute; President, British Society For Gene And Cell Therapy; | Imperiai College London » speaking at Advanced Therapies

Felipe Guapo, Analytical Scientist, NIBRT

Chris Hackley, Chief Executive Officer, Eucalyptus Bio

Eric Halioua, President & Chief Executive Officer, PDC*line pharma SA

Eric Halioua | President & Chief Executive Officer | PDC*line pharma SA » speaking at Advanced Therapies

Patrick Hanley, Chief and Director, Cellular Therapy Program, Children's National Medical Center

Günter Harms, Senior Director, Patient Access, Germany, Austria, Switzerland, Novartis Gene Therapies

Günter Harms | Senior Director, Patient Access, Germany, Austria, Switzerland | Novartis Gene Therapies » speaking at Advanced Therapies

Alexandra Harrison, PhD Student, University of Bristol

Alexandra Harrison | PhD Student | University of Bristol » speaking at Advanced Therapies

Thomas Hauser, Sales Director EMEA, C-Cube

David Hay, Chief Executive Officer, Stimuliver

Amir Hefni, VP, Global Commercial Head, Cell & Gene, Novartis

Amir Hefni | VP, Global Commercial Head, Cell & Gene | Novartis » speaking at Advanced Therapies

Sam Hickman, Field Application Specialist, Albumedix Ltd. - NOTTINGHAM

Edward Hodgkin, Managing Partner, Syncona

Edward Hodgkin | Managing Partner | Syncona » speaking at Advanced Therapies

Kevin Holden, Head of Science, Synthego Corporation

Yi-Ting Hu, Researcher, University College London

Yi-Ting Hu | Researcher | University College London » speaking at Advanced Therapies

Adam Inche, CEO, Lentitek

Melita Irving, Group Leader T-Cell Engineering, University of Lausanne

Melita Irving | Group Leader T-Cell Engineering | University of Lausanne » speaking at Advanced Therapies

Ryotaro Ishikawa, Region Europe Gene Therapies Value and Access Head, Novartis

Kathy Ivey, Vice President of Gene Therapy Research, Tenaya Therapeutics

Kathy Ivey | Vice President of Gene Therapy Research | Tenaya Therapeutics » speaking at Advanced Therapies

Russell Jarres, Sr. Manager, Strategic Collaborations, Thermo Fisher Scientific

Inge Jedema, Head of Translational Cellular Therapy, Netherlands Cancer Institute / Antoni van Leeuwenhoek

Pia Johansson, Director, Cell and Gene Therapy Core, Lund University

Jason Jones, Global Business Development Lead, Cellular Origins

Ron Jortner, Founder & Chief Executive Officer, Aspire Biosciences

Ron Jortner | Founder & Chief Executive Officer | Aspire Biosciences » speaking at Advanced Therapies

Margareth Jorvid, Head of Regulatory Affairs, Ilya Pharma

Margareth Jorvid | Head of Regulatory Affairs | Ilya Pharma » speaking at Advanced Therapies

Angela Justice, Chief People Officer, Justice Group Advisors

Angela Justice | Chief People Officer | Justice Group Advisors » speaking at Advanced Therapies

Cornelia Kasper, Head of Institute for Cell and Tissue Culture Technologies, University Of Natural Resources And Life Sciences Vienna

Cornelia Kasper | Head of Institute for Cell and Tissue Culture Technologies | University Of Natural Resources And Life Sciences Vienna » speaking at Advanced Therapies

Jasmin Kee, Bioprocessing Consultant, KeeBio

Jasmin Kee | Bioprocessing Consultant | KeeBio » speaking at Advanced Therapies

Kilian Kelly, Chief Executive Officer & Managing Director, Cynata Therapeutics Ltd

Sven Kili, Chief Development Officer, CCRM & Principal, Sven Kili Consulting

Sven Kili | Chief Development Officer, CCRM & Principal | Sven Kili Consulting » speaking at Advanced Therapies

Laura Koivusalo, Chief Executive Officer & Founder, StemSight

Laura Koivusalo | Chief Executive Officer & Founder | StemSight » speaking at Advanced Therapies

Bence Kozma, Research Assistant PostDoc, TU Wien

Bence Kozma | Research Assistant PostDoc | TU Wien » speaking at Advanced Therapies

David Kuntin, Chief Executive Officer, MesenBio

David Kuntin | Chief Executive Officer | MesenBio » speaking at Advanced Therapies

Joanne Kurtzberg, Professor Of Pediatrics And Pathology; Director, Marcus Center For Cellular Cures,, Duke University Medical Center

Joanne Kurtzberg | Professor Of Pediatrics And Pathology; Director, Marcus Center For Cellular Cures, | Duke University Medical Center » speaking at Advanced Therapies

Michael Kyriakides, Investment partner, Syncona Ltd

Michael Kyriakides | Investment partner | Syncona Ltd » speaking at Advanced Therapies

Pauline L' Hénaff, Head of Industry Engagement, Access to Medicine Foundation

Michele Lai, Researcher, University of Pisa

Michele Lai | Researcher | University of Pisa » speaking at Advanced Therapies

Marcos Langtry, Director, Commercial Development, CGT, Lonza

Holger Laux, Director of Viral Vector Process Development, CSL Behring

Holger Laux | Director of Viral Vector Process Development | CSL Behring » speaking at Advanced Therapies

Nick Lench, Executive Director, Nucleic Acid Therapy Accelerator (NATA)

Nick Lench | Executive Director | Nucleic Acid Therapy Accelerator (NATA) » speaking at Advanced Therapies

Hanna Lesch, CTO, Exothera

Bruce Levine, Professor, Perelman School of Medicine University of Pennsylvania

Doreen Li, CFO, Santo Therapeutics

Doreen Li | CFO | Santo Therapeutics » speaking at Advanced Therapies

Roel Lievrouw, Downstream Process Development Manager, Exothera SA

Roel Lievrouw | Downstream Process Development Manager | Exothera SA » speaking at Advanced Therapies

Rosie Lindup, Policy and Public Affairs Manager, Bia

Gisela Linthorst, Head of Patient Engagement and Advocacy, Azafaros

Gisela Linthorst | Head of Patient Engagement and Advocacy | Azafaros » speaking at Advanced Therapies

Raquel Loreto, Scientist, Batavia Biosciences

Tarik Luisman, Director Bioinformatics & Digital Systems, GeneScape

John Maher, CSO, Leucid Bio

John Maher | CSO | Leucid Bio » speaking at Advanced Therapies

Alberto Malerba, Lecturer in Gene Therapy, royal holloway university of london

Peter Marks, Director, Center For Biologics Evaluation And Research (CBER), U.S. Food and Drug Administration

Peter Marks | Director, Center For Biologics Evaluation And Research (CBER) | U.S. Food and Drug Administration » speaking at Advanced Therapies

Paolo Martini, CSO Rare Diseases, Hematology and Rare Alliances,, Moderna Therapeutics

Paolo Martini | CSO Rare Diseases, Hematology and Rare Alliances, | Moderna Therapeutics » speaking at Advanced Therapies

Yoshiaki Maruyama, Director, Office of Cellular and Tissue-based Products, Pharmaceuticals and Medical Devices Agency (PMDA), Japan

Julius Mathews, Project Manager & Research Fellow, Fraunhofer Institute for Production Technology IPT

Toni Mathieson, Chief Executive, Niemann-Pick UK

Toni Mathieson | Chief Executive | Niemann-Pick UK » speaking at Advanced Therapies

Vasily Medvedev, Head of Development, Exothera

Vasily Medvedev | Head of Development | Exothera » speaking at Advanced Therapies

Emily Merrell, Director of Centre for Cell & Gene Therapy, ICON PLC

Imen Mestiri, Business Development Manager, Genethon

Imen Mestiri | Business Development Manager | Genethon » speaking at Advanced Therapies

Jo Miller, Director, Cell Therapy Sciences

Jo Miller | Director | Cell Therapy Sciences » speaking at Advanced Therapies

Anji Miller, Skills Lead, Innovation Hubs for Gene Therapies/Director Translational Skills, LifeArc

Diego Möckli, Head of TechOps Strategy and Supply Chain, Tigen Pharma

Deana Mohr, Chief Executive Officer, MUVON Therapeutics

Deana Mohr | Chief Executive Officer | MUVON Therapeutics » speaking at Advanced Therapies

Sandrine Morel, Research Scientist, Universite de Geneve

Sandrine Morel | Research Scientist | Universite de Geneve » speaking at Advanced Therapies

Ismael Moreno Sánchez, Margarita Salas Postdoctoral Researcher, University Pablo de Olavide de Sevilla

Sandrine Mores, COO, EXO Biologics

Paolo Morgese, Head of Public Affairs, Europe, Alliance for Regenerative Medicine

Paolo Morgese | Head of Public Affairs, Europe | Alliance for Regenerative Medicine » speaking at Advanced Therapies

David Morrow, scientist, eatris

David Morrow | scientist | eatris » speaking at Advanced Therapies

Phil Morton, CTO, Albumedix Ltd

Sophie Mountcastle, Network Manager - Innovation Hubs for Gene Therapies, Innovation Hubs for Gene Therapies

Sophie Mountcastle | Network Manager - Innovation Hubs for Gene Therapies | Innovation Hubs for Gene Therapies » speaking at Advanced Therapies

Matthias Müllner, Chief Executive Officer, bespark*bio

Julien Muzard, Field Applications Technologist, ENTEGRIS

Snehal Naik, Head of Regulatory Policy; Strategy Leader (Ocular), Spark Therapeutics

Snehal Naik | Head of Regulatory Policy; Strategy Leader (Ocular) | Spark Therapeutics » speaking at Advanced Therapies

Michael Nation, Director of Development, Kidney Reseach U.K.

Alexander Natz, Director General, EUCOPE - European Confederation of Pharmaceutical Entrepreneurs

Alexander Natz | Director General | EUCOPE - European Confederation of Pharmaceutical Entrepreneurs » speaking at Advanced Therapies

Jan Nelis, CEO & Co-Founder, Ariya Bio

Katy Newton, Senior Vice President of Immunology and Process Development, Achilles Therapeutics Limited

Joanne Ng, Senior Research Fellow, University College London

Joanne Ng | Senior Research Fellow | University College London » speaking at Advanced Therapies

Josefina Nilsson, Chief Executive Officer, QuTEM AB

Roberto Nitsch, Director, Astrazeneca

Roberto Nitsch | Director | Astrazeneca » speaking at Advanced Therapies

Raphael Ognar, President & Chief Executive Officer, Co-Founder, NKILT Therapeutics Inc.

Willy Oliveira, Business Development Manager, Integra Therapeutics

Christina O'Neill, Chief Executive Officer, VascVersa

Nneka Onwudiwe, Former PRO/PE Regulatory Review Officer, Food and Drug Administration (FDA)

Nneka Onwudiwe | Former PRO/PE Regulatory Review Officer | Food and Drug Administration (FDA) » speaking at Advanced Therapies

Dominic O'Regan, Business Development Consultant & Investor, New Mosaic

Dominic O'Regan | Business Development Consultant & Investor | New Mosaic » speaking at Advanced Therapies

George Pamenter, PhD Researcher, UCL

Vashu Pamnani, Senior Business Development Manager, Research Donors

Kerstin Papenfuss, Director Pharma, Deep Science Ventures

Kerstin Papenfuss | Director Pharma | Deep Science Ventures » speaking at Advanced Therapies

Shree Patel, EVP Patient Supply Operations, Achilles Therapeutics Limited

Shree Patel | EVP Patient Supply Operations | Achilles Therapeutics Limited » speaking at Advanced Therapies

Rik Patel, Senior Trade Manager, London & Partners

Tom Payne, Chief Operating Officer, Laverock Therapeutics

Henry Pegram, Head of Business Development, Kings College London Gene Therapy Vector Facility

Henry Pegram | Head of Business Development | Kings College London Gene Therapy Vector Facility » speaking at Advanced Therapies

David Peritt, Chief Scientific Officer, Lupagen

Madhusudan Peshwa, CTO, Tessera Therapeutics

Carlotta Peticone, Principal Scientist, Orchard Therapeutics

Paola Pozzi, Partner, Sofinnova Partners

Thomas Prod'homme, Vice President, Translational Research, Myeloid Therapeutics

Thomas Prod'homme | Vice President, Translational Research | Myeloid Therapeutics » speaking at Advanced Therapies

Amelie Quilichini, Chief Executive Officer and Co-Founder, Kolibri

Valentin Quiniou, CSO, Parean Biotechnologies

Valentin Quiniou | CSO | Parean Biotechnologies » speaking at Advanced Therapies

Vittoria Raffa, Professor, University of Pisa

Qasim Rafiq, Associate Professor in Cell and Gene Therapy Bioprocess Engineering, University College London

Liz Ramsburg, Head of Neuroscience Research, Spark Therapeutics

Linda Randall, Associate VP, Biologics Development, Manufacturing & Control, Pharmaron

Lior Raviv, CTO, Pluri

Lior Raviv | CTO | Pluri » speaking at Advanced Therapies

Nicola Redfern, Director, NJ Redfern Ltd.

Nicola Redfern | Director | NJ Redfern Ltd. » speaking at Advanced Therapies

Thomas Robert, Product Manager, Univercells Technologies

Jessica Robinson, PD, Terrapinn

Jessica Robinson | PD | Terrapinn » speaking at Advanced Therapies

Josh Robinson, Chief Executive Officer, COCOON BIOSCIENCE

Andre Roeder, Head, Commercial Operations EU, TETEC AG

Andre Roeder | Head, Commercial Operations EU | TETEC AG » speaking at Advanced Therapies

Sean Russell, Head of Translational Project Management & Regulatory Affairs, Telethon Foundation

Sean Russell | Head of Translational Project Management & Regulatory Affairs | Telethon Foundation » speaking at Advanced Therapies

Pooja Sabhachandani, Associate Director, Tessera Therapeutics

Pooja Sabhachandani | Associate Director | Tessera Therapeutics » speaking at Advanced Therapies

Tara Sadeghi, Chief Operating Officer, Cellenkos

Moin Saleem, Founder and Chief Scientific Advisor, Purespring Therapeutics

Moin Saleem | Founder and Chief Scientific Advisor | Purespring Therapeutics » speaking at Advanced Therapies

Caroline Savage, Professor of Nephrology, University of Birmingham

Caroline Savage | Professor of Nephrology | University of Birmingham » speaking at Advanced Therapies

Mark Sawicki, Chief Executive Officer, Cryoport Systems

Christian Schenk, Industry Lead Life Sciences, time matters

Christian Schenk | Industry Lead Life Sciences | time matters » speaking at Advanced Therapies

Fatma Senkesen, Executive Director, Head Divisional Projects C&G, Lonza

Fatma Senkesen | Executive Director, Head Divisional Projects C&G | Lonza » speaking at Advanced Therapies

Tanya sharma, cofounder, Assurea LLC

Tanya sharma | cofounder | Assurea LLC » speaking at Advanced Therapies

Leigh Shaw, SVP, Head of Regulatory Affairs and Non-Clinical Safety, Toxicology & Biodistribution, Bloomsbury Genetic Therapies

Daniel Shelly, Vice President Business Development and Alliances, Prescient Therapeutics

Daniel Shelly | Vice President Business Development and Alliances | Prescient Therapeutics » speaking at Advanced Therapies

Alex Shephard, Product Manager, Unchained Labs

Kevin Smith, Head of Technology Development: Synthetic Biology, Cell Line Development, Process Development, Asimov

Kevin Smith | Head of Technology Development: Synthetic Biology, Cell Line Development, Process Development | Asimov » speaking at Advanced Therapies

Devyn Smith, Chief Executive Officer, Arbor Biotechnologies

Devyn Smith | Chief Executive Officer | Arbor Biotechnologies » speaking at Advanced Therapies

Owen Smith, Partner, 4BIO Capital

Owen Smith | Partner | 4BIO Capital » speaking at Advanced Therapies

Ludek Sojka, Chief Executive Officer, SCTbio

Ludek Sojka | Chief Executive Officer | SCTbio » speaking at Advanced Therapies

Joseph Stavas, Senior Vice President of Clinical Development, ProKidney

Joseph Stavas | Senior Vice President of Clinical Development | ProKidney » speaking at Advanced Therapies

Jenny Stjernberg, Commercial Director, EMEA, ScaleReady

Mark Stockdale, Senior Director of Strategic Alliances, Asimov

Matthias Stöcker, Capability Lead, Boehringer-Ingelheim

Matthias Stöcker | Capability Lead | Boehringer-Ingelheim » speaking at Advanced Therapies

Nicola Stoner, Consultant Pharmacist, Oxford University Hospitals N.H.S. Trust

Nicola Stoner | Consultant Pharmacist | Oxford University Hospitals N.H.S. Trust » speaking at Advanced Therapies

Stephen Sullivan, COO, iPSirius

Stephen Sullivan | COO | iPSirius » speaking at Advanced Therapies

Marina Tarunina, Research Director, Plasticell

Marina Tarunina | Research Director | Plasticell » speaking at Advanced Therapies

George Tetley, CSO, Deliver Biosciences

Stefanos Theoharis, Chief Executive Officer, OneChain Immunotherapeutics

Stefanos Theoharis | Chief Executive Officer | OneChain Immunotherapeutics » speaking at Advanced Therapies

Steven Thompson, Vice President, Sales - Cell Processing, BioLife Solutions

Steven Thompson | Vice President, Sales - Cell Processing | BioLife Solutions » speaking at Advanced Therapies

Mya Thu, Co-Founder and Chief Executive Officer, Visicell Medical Inc.

Pamela Tranter, Head, Translational Research Group, Translational Research Office, University College London

Pamela Tranter | Head, Translational Research Group, Translational Research Office | University College London » speaking at Advanced Therapies

Marco Traub, Chief Executive Officer, Tesct—Society

Prof. Dr. Andrea Tüttenberg, Chief Executive Officer, ActiTrexx GmbH

Prof. Dr.  Andrea Tüttenberg | Chief Executive Officer | ActiTrexx GmbH » speaking at Advanced Therapies

Christopher Ullman, Co-founder and Chief Executive Officer, Stratosvir Limited

Christopher Ullman | Co-founder and Chief Executive Officer | Stratosvir Limited » speaking at Advanced Therapies

Stefanie Urlinger, Chief Scientific Officer, Cimeio Therapeutics

Joris van Arensbergen, Chief Executive Officer, Annogen BV

Joris van Arensbergen | Chief Executive Officer | Annogen BV » speaking at Advanced Therapies

Melissa van Pel, Head of Cell Therapy, NecstGen BV

Melissa van Pel | Head of Cell Therapy | NecstGen BV » speaking at Advanced Therapies

Marijn Verhoef, Director of Research and Operations, Access to Medicine Foundation

Marijn Verhoef | Director of Research and Operations | Access to Medicine Foundation » speaking at Advanced Therapies

Maria Jacintha Victoria, Analytical Development Team Lead, Rentschler Biopharma

Ketki Vispute, Associate Director of Production, Autolus

Ketki Vispute | Associate Director of Production | Autolus » speaking at Advanced Therapies

Michael von Forstner, Head of Safety Science, Global Pharmacovigilance and Patient Safety, Sobi (Swedish Orphan Biovitrum)

Michael von Forstner | Head of Safety Science, Global Pharmacovigilance and Patient Safety | Sobi (Swedish Orphan Biovitrum) » speaking at Advanced Therapies

Ivan Wall, Professor, FourPlus Immersive Ltd.

Ivan Wall | Professor | FourPlus Immersive Ltd. » speaking at Advanced Therapies

Ruizhi Wang, Chief Executive Officer/Founder, Abselion

Natalie Ward, Director, Regulatory Affairs CMC, Adaptimmune

Natalie Ward | Director, Regulatory Affairs CMC | Adaptimmune » speaking at Advanced Therapies

Neil Watson, Director Of Northern Alliance Attc, Northern Alliance Advanced Therapies Treatment Centre

Neil Watson | Director Of Northern Alliance Attc | Northern Alliance Advanced Therapies Treatment Centre » speaking at Advanced Therapies

Ben Weil, Director of Manufacturing, INmune Bio

Theodora Weisz, Head of Patient Advocacy and Public Affairs, Novartis Gene Therapies, Novartis Gene Therapies

Anna Louisa Weltin, Research Fellow, Fraunhofer IPT

Caroline Weydert, RSS genomics, Bio-Rad

Nathan White, Research Associate, UCL

Darius Widera, Professor of Stem Cell Biology and Regenerative Medicine, University of Reading

Sue Williams, Managing Director, Hexagon Consultants Ltd.

Sue Williams | Managing Director | Hexagon Consultants Ltd. » speaking at Advanced Therapies

Chris Williams, SVP, Corporate Development, Autolus Therapeutics

Chris Williams | SVP, Corporate Development | Autolus Therapeutics » speaking at Advanced Therapies

Andrew Willis, Chief Development and Regulatory Officer, Lift Biosciences Ltd

Debbie Worthing, Lead Research Nurse, Advanced Therapies Wales, Welsh Blood Service

Debbie Worthing | Lead Research Nurse, Advanced Therapies Wales | Welsh Blood Service » speaking at Advanced Therapies

Kris Wronski, Cell Culture Applications Scientist, Thermo Fisher Scientific

Sujeong Yang, Senior Research Scientist, Astrea Bioseparations

Kikuo Yasui, Chief Operating Officer, Director of the Board, Heartseed Inc.

Kikuo Yasui | Chief Operating Officer, Director of the Board | Heartseed Inc. » speaking at Advanced Therapies

Mana Yen, Global Executive Director - Health systems, Novartis Gene Therapies

Mana Yen | Global Executive Director - Health systems | Novartis Gene Therapies » speaking at Advanced Therapies

Elisabetta Zanon, Director, European Policy and Advocacy, Alliance for Regenerative Medicine

Elisabetta Zanon | Director, European Policy and Advocacy | Alliance for Regenerative Medicine » speaking at Advanced Therapies

Andrea Zobel, Senior Director Personalized Supply Chain, World Courier

Michela Zuccolo, Gene Therapy and Rare Strategy, F. Hoffmann-La Roche

Michela Zuccolo | Gene Therapy and Rare Strategy | F. Hoffmann-La Roche » speaking at Advanced Therapies


Get Involved with the Advanced Therapies Congress

 

To sponsor or exhibit


Ashlea Foster
ashlea.foster@terrapinn.com
+44 208 164 3032

 

 

To speak


Ila Dickinson
ila.dickinson@terrapinn.com
+44 207 092 1150